Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 9:27:100725.
doi: 10.1016/j.ymgmr.2021.100725. eCollection 2021 Jun.

The Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS): Evaluation of a prototype in Finnish Gaucher disease patients and feasibility of screening retrospective electronic health record data for the recognition of potential undiagnosed patients in Finland

Affiliations

The Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS): Evaluation of a prototype in Finnish Gaucher disease patients and feasibility of screening retrospective electronic health record data for the recognition of potential undiagnosed patients in Finland

Markku J Savolainen et al. Mol Genet Metab Rep. .

Abstract

Background: Gaucher disease (GD) is a rare inherited multiorgan disorder, yet a diagnosis can be significantly delayed due to a broad spectrum of symptoms and lack of disease awareness. Recently, the prototype of a GD point-scoring system (PSS) was established by the Gaucher Earlier Diagnosis Consensus (GED-C) initiative, and more recently, validated in Gaucher patients in UK. In our study, the original GED-C PSS was tested in Finnish GD patients. Furthermore, the feasibility of point scoring large electronic health record (EHR) data set by data mining to identify potential undiagnosed GD cases was evaluated.

Methods: This biobank study was conducted in collaboration with two Finnish biobanks. Five previously diagnosed Finnish GD patients and ~ 170,000 adult biobank subjects were included in the study. The original PSS was locally adjusted due to data availability issues and applied to the Finnish EHR data representing special health care recordings.

Results: All GD patients had high levels of the biomarker lyso-Gb1 and deleterious GBA mutations. One patient was a compound heterozygote with a novel variant, potentially pathogenic mutation. Finnish EHR data allowed the retrospective assessment of 27-30 of the 32 original GED-C signs/co-variables. Total point scores of GD patients were high but variable, 6-18.5 points per patient (based on the available data on 28-29 signs/co-variables per patient). All GD patients had been recorded with anaemia while only three patients had a record of splenomegaly. 0.72% of biobank subjects were assigned at least 6 points but none of these potential "GD suspects" had a point score as high as 18.5. Splenomegaly had been recorded for 0.25% of biobank subjects and was associated with variable point score distribution and co-occurring ICD-10 diagnoses.

Discussion: This study provides an indicative GED-C PSS score range for confirmed GD patients, also representing potential mild cases, and demonstrates the feasibility of scoring Finnish EHR data by data mining in order to screen for undiagnosed GD patients. Further prioritisation of the "GD suspects" with more developed algorithms and data-mining approaches is needed.

Funding: This study was funded by Shire (now part of Takeda).

Keywords: Biobank study; DBS, dried blood spot; EHR, Electronic health record; Electronic health record; GBA; GBA1/GBA, β-glucocerebrosidase gene; GD, Gaucher disease; GED-C, The Gaucher Earlier Diagnosis Consensus; Gaucher disease; Gaucher earlier diagnosis consensus point-scoring system; GlcCer, β-glucosylceramide; GlcCerase, β-glucosylceramidase; GlcSph/Lyso-Gb1, β-glucosylsphingosine; HDSF, Hospital District of Southwest Finland; Lyso-Gb1; NOHD, Northern Ostrobothnia Hospital District; PSS, Point-scoring system.

PubMed Disclaimer

Conflict of interest statement

CVF and KE are employed by Takeda (Stockholm, Sweden and Helsinki, Finland, respectively). AK and SR are employed by Auria Biobank and Biobank Borealis, respectively, which received reimbursement from Shire (now part of Takeda), for the work done at Auria/Borealis. IT, KU, and MIL are employed by Medaffcon Oy (Espoo, Finland) which received funding from Shire (now part of Takeda), for conducting the study. MJS reports personal consultancy fees and travel grants from Shire (now part of Takeda) during the study, as well as grant support, paid to his institution, from several foundations for research outside the submitted work.

Figures

Fig. 1
Fig. 1
GED-C point-score distribution in the biobank population of the Hospital District of Southwest Finland. The figure shows the point-score distribution among all assessed adult subjects (N = 161,950). In the insert, the distribution among subjects with 6 points or more is magnified.

Similar articles

Cited by

References

    1. Brady R.O., Kanfer J.N., Shapiro D. Metabolism of glucocerebrosides II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem. Biophys. Res. Commun. 1965;18:221–225. doi: 10.1016/0006-291X(65)90743-6. - DOI - PubMed
    1. Dandana A., Ben Khelifa S., Chahed H., Miled A., Ferchichi S. Gaucher disease: clinical, biological and therapeutic aspects. Pathobiology. 2016;83:13–23. doi: 10.1159/000440865. - DOI - PubMed
    1. Stirnemann J., Belmatoug N., Camou F., Serratrice C., Froissart R., Caillaud C., Levade T., Astudillo L., Serratrice J., Brassier A., Rose C., Billette de Villemeur T., Berger M. A review of Gaucher disease pathophysiology, clinical presentation and treatments. IJMS. 2017;18:441. doi: 10.3390/ijms18020441. - DOI - PMC - PubMed
    1. Aerts J.M.F.G., Kallemeijn W.W., Wegdam W., Joao Ferraz M., van Breemen M.J., Dekker N., Kramer G., Poorthuis B.J., Groener J.E.M., Cox-Brinkman J., Rombach S.M., Hollak C.E.M., Linthorst G.E., Witte M.D., Gold H., van der Marel G.A., Overkleeft H.S., Boot R.G. Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies. J. Inherit. Metab. Dis. 2011;34:605–619. doi: 10.1007/s10545-011-9308-6. - DOI - PMC - PubMed
    1. Nilsson O., Månsson J.-E., Håk̈ansson G., Svennerholm L. The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of gaucher’s disease. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 1982;712:453–463. doi: 10.1016/0005-2760(82)90272-7. - DOI - PubMed

LinkOut - more resources